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Abstract 21 
Objectives: To identify indicators of the risk of progression of preclinical hypertrophic 22 
cardiomyopathy (HCM). 23 
Methods: A prospective cohort study following a population of cats with preclinical hypertrophic 24 
cardiomyopathy. Cats serially underwent physical examination, blood pressure measurement, blood 25 
sampling and echocardiography. Development of congestive heart failure (CHF), aortic 26 
thromboembolism (ATE) or sudden death (SD) were considered cardiac-related events. Associations 27 
between factors recorded at baseline, and on revisit examinations, and the development of a 28 
cardiac-related event were explored using ROC analysis. 29 
Results: 47 cats were recruited to the study and followed for a median period of 1135 days. 15 cats 30 
(31.9%) experienced at least one cardiac-related event; 6 CHF, 5 ATE and 5 SD. One cat experienced 31 
a cardiac-related event per 10.3 years of patient follow-up. Cats with increased left atrial (LA) size 32 
and higher concentrations of N-terminal B-Type Natriuretic peptide (NTproBNP) at baseline were 33 
more likely to experience an event. Cats with a greater rate of enlargement of left atrial size 34 
between examinations were also more likely to experience an event. 35 
Conclusions and relevance: Factors easily measured, either once or serially, in cats with preclinical 36 
HCM can help to identify those at greater risk of going on to develop clinical signs.  37 
  38 
 39 
Introduction. 40 
Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease of cats 1. It is estimated 41 
to affect as many as 16% of domestic cats 1-3. With the UK population of pet cats thought to number 42 
approximately 11.1 milliona there could be over a million affected cats in the UK. 43 
Although in some cats HCM is a progressive disease, many cats remain free from clinical signs for 44 
years 4, 5. Some cats do develop serious clinical complications including congestive heart failure, 45 
thromboembolism and sudden death 5-8. The challenge for veterinary surgeons is to distinguish 46 
those cats at greater risk of having progressive disease from those more likely to remain stable.  47 
Information of prognostic value can be gained from signalment and clinical examination.  Cats 48 
younger at the time of diagnosis have been shown to have a longer survival time 4, 8.  The presence 49 
of an arrhythmia and audible gallop have been associated with a worse outcome 9 and a detectable 50 
arrhythmia has been associated with a greater risk of sudden death10. 51 
Echocardiography has consistently been shown to provide information of prognostic value in cats 52 
with HCM. Increased left atrial size has been associated with shorter survival time and a higher 53 
likelihood of developing congestive heart failure, thromboembolism or experiencing sudden cardiac 54 
death 4, 8, 10-12.  Greater left ventricular wall thickness has also been associated with a greater risk of 55 
death 7, 9.  56 
More recently, two studies have demonstrated that measurement of cardiac biomarker 57 
concentrations may be of prognostic value 13, 14. Both studies showed that higher concentrations of 58 
circulating troponin were associated with a worse outcome. The study by Borgeat and others (2014) 59 
also demonstrated that an N-terminal pro B-type natriuretic peptide (NTproBNP) concentration of 60 
greater than 250 pmol/L was associated with a greater risk of cardiac death; however, this did not 61 
remain independently associated with a worse outcome when the presence of clinical signs and left 62 
atrial size were accounted for.  63 
The majority of studies of feline HCM in the literature have been retrospective studies and described 64 
populations of cats seen at referral centres by specialists. There is limited information about risk 65 
indicators in cats with pre-clinical HCM seen by non-specialists, outside the setting of a referral 66 
hospital. The aim of the current study was prospectively to follow a population of cats diagnosed 67 
 
a 2018 PDSA Animal Wellbeing (PAW) Report  
https://www.pdsa.org.uk/media/4371/paw-2018-full-web-ready.pdf  
with pre-clinical HCM; repeating clinical examination, systolic blood pressure measurement, blood 68 
tests (including cardiac biomarkers) and echocardiography approximately annually. 69 
We hypothesized that in a population of cats with preclinical HCM certain of these measurements 70 
would be of prognostic value and serial measurements would give additional valuable information 71 
regarding outcome. 72 
Materials and methods 73 
Setting  74 
Cats with HCM were identified from among cats with heart murmurs that were referred for further 75 
investigation from first opinion veterinarians in northern England to one of two investigators both 76 
RCVS cardiology certificate holders (VI and PT) between July 2010 and November 2015. Cats 77 
underwent examination either in the practice in which they would normally be examined or in 78 
another primary care practice near to their usual practice. Owners gave informed consent for their 79 
cats to be enrolled in the study. All the procedures undertaken as part of the study were standard 80 
diagnostic and monitoring procedures appropriate for patients with preclinical hypertrophic 81 
cardiomyopathy and therefore the protocol did not undergo ethical review. The study underwent 82 
review and was funded by Petsavers. 83 
Cats underwent a full clinical examination, systolic blood pressure measurement, blood tests and 84 
echocardiography.  85 
Physical Exam 86 
A complete physical examination was performed at each point of contact with each patient.  Body 87 
weight, condition score and pulse quality were recorded.  Murmur intensity, the presence or 88 
absence of gallop sounds, the presence or absence of arrhythmias, heart rate and lung sounds were 89 
noted after thoracic auscultation. 90 
Blood pressure measurement 91 
Systolic blood pressure was measured non-invasively by Doppler sphygmomanometry (Ultrasonic 92 
Doppler flow detector, Model 811-B, Parks Medical Electronics Inc, Aloha, OR, USA) prior to 93 
collection of blood. Cuffs were placed on the right or left forelimb, and a mean of three consecutive 94 
readings was recorded. 95 
Blood tests 96 
Blood was collected by jugular venepuncture into plain, serum gel and EDTA tubes.  After clotting, 97 
plain tube samples were centrifuged and the serum transferred to a clean plain tube. The serum gel 98 
and an EDTA tube were centrifuged within 5 minutes of collection.  EDTA plasma was then separated 99 
into a plain tube.  A separate EDTA tube was submitted to the laboratory with a freshly prepared 100 
blood film.  Samples were refrigerated and then sent via courier to a commercial laboratory (Idexx 101 
Laboratories, Wetherby) for the following tests:  urea, creatinine, glucose, alanine aminotransferase 102 
(ALT), sodium, potassium, total thyroxine, cardiac troponin Ib (cTnI), NTproBNPc, and a complete 103 
blood count.  104 
Echocardiography 105 
For each echocardiographic examination cats were clipped and placed in right and then left lateral 106 
recumbency on an ultrasound examination table.  An ultrasound unit equipped with a 3.5-8 MHz 107 
probe and ECG monitoring (Vivid-I, 7S-RS probe, GE Medical Systems, Milwaukee, WI, USA) was used 108 
for all examinations.  Each cat had all echocardiographic examinations performed by the same 109 
observer.  110 
 A standard echocardiographic examination was performed 15 using the using the 7S-RS probe at an 111 
appropriate frequency setting to optimise image quality. Simultaneous ECG monitoring was achieved 112 
for all cats except those intolerant of the ECG leads. Images were digitally stored and measurements 113 
were obtained from still or looped images.  All reported linear measurements were obtained from 114 
two-dimensional images. Echocardiographic variables obtained were the average of at least 3 115 
measurements from discrete cardiac cycles.  The following parameters were measured at each 116 
echocardiographic examination. The long axis left atrial measurement i.e. the maximal dimension 117 
parallel to the plane of the mitral annulus measured at end-ventricular systole was measured in the 118 
frame just before the mitral valve opening 16.  The left atrial and aortic dimensions were obtained 119 
from short-axis images. They were measured on the first diastolic frame obtained after closure of 120 
the aortic valve.  The aorta was measured parallel to the commissure of the non- and right-coronary 121 
aortic valve cusps. The left atrial dimension was measured parallel to the commissure of the left- and 122 
noncoronary aortic valve cusps.  The ratio of left atrial size to aortic root was then calculated 17. 123 
The thickness of the left ventricular free wall and interventricular septum were both measured in 124 
diastole using the leading edge method 18.  Focal or generalized hypertrophy was characterized by a 125 
thickness of ≥ 6 mm 7.  The left ventricular outflow tract maximal velocity was recorded from the left 126 
parasternal long axis view.  In addition, the presence or absence of the following were noted: 127 
 
b Beckman Coulter high sensitivity TnI. 
c First-generation Cardiopet proBNP assay until August 2013, second-generation Cardiopet proBNP assay 
thereafter. 
systolic anterior motion of the mitral valve (SAM); chordal anterior motion (CAM); and whether a 128 
dynamic left ventricular outflow velocity profile was observed 19. 129 
If sedation was needed in order to complete the examinations 2.5 mg/kg ketamine (Anaestamine; 130 
Animalcare) and 0.25 mg/kg midazolam (Hypnovel; Roche) were given intravenously via an IV 131 
cannula. 132 
Enrolment criteria 133 
Cats were recruited to the study during the period from July 2010 to November 2015.  134 
Cats were considered eligible for inclusion in the study if diagnosed with preclinical HCM. HCM was 135 
diagnosed if evidence was found of left ventricular segmental or diffuse hypertrophy of unknown 136 
origin (interventricular septum (IVS) and/or left ventricular free wall (LVFW) thickness in diastole was 137 
≥ 6mm) 7. 138 
Cats were excluded if they were found to have a cardiac disease other than HCM, clinical signs 139 
associated with HCM, or other clinically relevant disease including hypertension, hyperthyroidism, 140 
diabetes mellitus, anaemia (a red blood cell count below the reference interval of the laboratory) 141 
and azotaemia.  142 
After the initial diagnosis, owners of cats with an aortic velocity of ≥ 4m/s were offered the option of 143 
using atenolol at a dose rate of 6.25 mg SID or BID.  No other cardiac medication was offered at this 144 
stage. 145 
Follow up 146 
Re-examinations were scheduled at approximately yearly intervals for two years after the baseline 147 
visit. At re-examination cats underwent the same tests as were performed at baseline. Examinations 148 
performed on individual cats were always repeated by the same investigator. 149 
If follow up echocardiography showed left atrial enlargement, clopidogrel for prevention of 150 
thrombo-embolism was discussed with the owners.  If used, the dose was 18.75 mg SID. Atenolol 151 
treatment was stopped if atrial dilation was noted. 152 
Cats were followed until they experienced a cardiac-related event, were lost to follow up, died (of 153 
any cause), or the study was concluded. A cat was considered to have experienced a cardiac-related 154 
event if any of the following occurred; the cat experienced a thromboembolic event, developed 155 
signs consistent with congestive heart failure (CHF) that required treatment or experienced sudden 156 
death, assumed to be cardiac in origin.  157 
Diagnosis of arterial thromboembolism (ATE) was made on the basis of characteristic clinical signs of 158 
the occlusion of arterial blood supply to at least one limb. A diagnosis of CHF was made on the basis 159 
of a cat developing clinical signs of tachypnoea and dyspnoea in the absence of another cause. The 160 
presence of the following were considered to corroborate a clinical diagnosis of heart failure; 161 
audible pulmonary crackles, a response to diuretic therapy, pulmonary infiltrates on a thoracic 162 
radiograph and/or a pleural effusion on thoracic ultrasound. A cat was considered to have 163 
experienced sudden death as its first cardiac related event if it was found dead by the owner having 164 
been known to be normal less than 24 hours prior to being found dead in the absence of an 165 
alternative explanation for the death. 166 
The study was concluded in March 2018. 167 
The primary outcome of interest was whether or not a cat experienced a cardiac-related event 168 
during the period of follow up. 169 
The following variables were recorded at baseline sex (male/female), age (years) and breed 170 
(pedigree/not). The following variables were recorded at baseline and at each re-examination;, body 171 
weight (Kg), heart rate (bpm), murmur intensity (/6), systolic blood pressure (mmHg), BUN (mg/dL), 172 
NTproBNP (pmol/L), cTn I (ng/mL), maximum left ventricular wall thickness in diastole (mm), LA:Ao 173 
ratio, left atrial diameter in long axis, maximum aortic velocity (m/s), treated with atenolol (yes/no) 174 
and the presence of an arrhythmia (y/n).  175 
The upper limit of detection of the NTproBNP assay was 1500 pmol/L, cats with values above the 176 
upper limit were ascribed a concentration of 1500 pmol/L. 177 
An a priori power analysis was not conducted but the study planned to recruit fifty cats.  178 
Statistical analysis 179 
Descriptive statistics for continuous variables are reported as median values and range; for 180 
categorical and ordinal variables, they are reported as frequency and proportions.  181 
Variables at baseline were compared between cats that went on to experience an event and those 182 
that did not. Continuous variables were compared using an independent samples Mann-Whitney U 183 
test. Categorical variables were compared with a Chi-square or Fisher’s exact as appropriate.  184 
Those variables where the distribution differed significantly between cats that experienced an event 185 
and those that did not were evaluated further for their ability to discriminate between the two 186 
groups using ROC analysis. A cut-off value was calculated with the best discriminatory ability on the 187 
basis of the co-ordinate points of the ROC curve and commonly used cut-off values. 188 
For the two variables shown by the ROC analysis to best discriminate between cats experiencing an 189 
event and those that did not, the predictive ability of combining these variables was examined. Cats 190 
were classified as having none, one or both values of these variables above the cut-offs determined 191 
by the ROC analysis and the proportions of cats in each group were compared for likelihood of 192 
experiencing an event.  193 
Time to event analyses were undertaken comparing cats with neither, one or both values of 194 
variables above the chosen cut-offs using Kaplan-Meier and Log-rank analysis. Cats that were lost to 195 
follow up, died of a non-cardiac cause or survived until the end of the study were right-censored in 196 
the analysis at the point of their last known contact with investigators or the time of death.  197 
Finally, a graph was plotted with values of the two variables on the axes illustrating those cats that 198 
did and did not experience an event. 199 
To determine whether cats at risk of an event could be identified by repeated measurement of 200 
characteristics identified to be associated with the likelihood of an event at baseline, the following 201 
analyses were undertaken. For those variables that differed significantly between cats that 202 
subsequently experienced an event and those that did not at the baseline visit, values for the 203 
absolute change in the variable ((measurement at visit n+1) – (measurement at visit n)) and the 204 
percentage change in the variable between visits were calculated (100*((measurement at visit n+1) 205 
– (measurement at visit n))/(measurement at visit n)). The absolute and percentage change of each 206 
variable from the previous visit were compared between cats that subsequently experienced an 207 
event and those that did not. For those variables that demonstrated a significant difference between 208 
groups, an ROC curve was plotted using the absolute or percentage change in the variable as the 209 
discriminator and subsequent event yes/no as the outcome. 210 
Results 211 
47 cats were diagnosed with preclinical HCM and recruited to the study. Baseline characteristics of 212 
the cats are summarised in Table 1. 213 
Of the 47 cats, fifteen experienced at least one cardiac-related event (32%); six developed signs 214 
consistent with CHF (13%), five experienced sudden death (11%) and five experienced ATE (9%). One 215 
cat experienced CHF and ATE concurrently. Four cats experienced death due to non-cardiac causes 216 
(9%). Twenty eight cats (60%) were alive and known not to have experienced a cardiac-related event 217 
at the time of last contact with the investigators. Figure 1 is a flow chart illustrating the outcome for 218 
all 47 cats recruited to the study. 219 
The median time of follow up for all cats in the study was 1135 days (range 215 – 2456 days) i.e. 220 
greater than 3 years. The median time in study for those cats that experienced an event was 1016 221 
days (range 215 – 1811 days). The median time in study for those cats that did not experience an 222 
event was 1210.5 days (range 264 – 2456 days). In total there were 56,444 days (154.6 years) of 223 
patient follow up meaning that there was one event per 10.3 years of patient follow up giving an 224 
incidence rate of 9.7% (95% CI 5.4 – 16%) per year. 225 
Eight cats required sedation in order to perform at least one of their echocardiographic 226 
examinations. Seven cats required sedation at the first examination of which five were subsequently 227 
examined (once n = 2 or twice n = 3) without the need for sedation. One cat sedated at the initial 228 
examination required sedation at both subsequent examinations and one cat required sedation at 229 
the second re-examination only. One cat that did not require sedation at the baseline visit and first 230 
re-examination required sedation for the second re-examination. 231 
Baseline variables that differed significantly between cats going on to experience an event and those 232 
that did not were as follows; LA:Ao ratio (p < 0.001), NTproBNP concentration (p = 0.001) and LA 233 
long axis measurement (p = 0.025). For all three variables, values were higher in the group of cats 234 
that went on to experience an event.  235 
Results of the ROC analysis testing the ability of these three variables to discriminate between those 236 
cats that went on to experience an event and those cats that did not are illustrated in table 2. Cut-off 237 
values are derived from the co-ordinate points of the ROC curves for the two most promising 238 
discriminators and the sensitivity, specificity and positive and negative likelihood ratios calculated on 239 
the basis of these cut-offs. 240 
The numbers of cats experiencing an event (and not experiencing an event) according to whether 241 
they had none, one or both risk indicators above the proposed cut offs are reported in tables 3 and 242 
4. A Kaplan Meier graph illustrating the proportion of cats remaining free of an event against time 243 
for the three groups of cats (neither risk indicator elevated, one risk indicator elevated, and both risk 244 
indicators elevated) is shown in Figure 2. Cats without either risk factor were significant less likely to 245 
experience an event compared to those with one factor (P = 0.018) and cats with both risk factors (P 246 
< 0.001). The median time to event was not reached in the group with neither risk factor. The 247 
median time to event was 1693 days (95% CI 665 - 2720 days) for cats with one risk factor and 1016 248 
days (95% CI 647 – 1384 days) for cats with both risk factors however the difference between these 249 
groups was not significant (P = 0.124). 250 
A graph illustrating the concentrations of NTproBNP and left atrial to aortic ratios of individual cats 251 
measured at baseline is illustrated in Figure 3. Those cats that experienced sudden cardiac death 252 
appear as red dots, those that experienced CHF appear as blue dots and those that experienced ATE 253 
appear as yellow dots. Those that did not experience an event appear as black dots. 254 
A significantly greater proportion of cats that experienced an event received atenolol at some point 255 
during their follow-up (P = 0.046). 256 
At the first revisit examination the absolute and percentage change in LA:Ao, LA Long and NTproBNP 257 
concentration did not differ between cats that went on to experience an event and those that did 258 
not (Table 5a). At the second revisit the absolute and percentage change in LA:Ao from the previous 259 
visit were greater in cats that went on to experience an event (Table 5b). The absolute change in the 260 
NTproBNP concentration was lower in those cats that went on to experience an event compared to 261 
those that did not (Table 5b). The absolute and percentage change in LA:Ao were significantly 262 
associated with the likelihood of an event in the ROC analysis (Table 6). As can be seen from figure 1, 263 
ten events occurred after the second revisit examination and data were only available for nine of 264 
those cats representing only 60% of all cats that experienced an event. 265 
Discussion 266 
This is the first study to prospectively follow a cohort of cats with preclinical hypertrophic 267 
cardiomyopathy managed in a primary care setting by non-specialists. It provides additional 268 
information about the natural history of this common disease, confirms the value of known 269 
echocardiographic risk indicators and demonstrates the value of measurement of circulating 270 
biomarkers in identifying cats at greater risk of going on to experience a cardiac-related event. It also 271 
provides information regarding the value of serial evaluation of risk indicators. 272 
The findings in the described population of cats confirm that many cats with pre-clinical 273 
hypertrophic cardiomyopathy can live for long periods without experiencing a cardiac-related event. 274 
It has previously been reported that for many cats with HCM, particularly those that are free of 275 
clinical signs at the time of diagnosis, the disease can be a relatively benign and slowly progressive or 276 
non-progressive 4, 5, 11. In the current study, during more than 150 years of patient follow up only 15 277 
cats experienced cardiac-related events, occurring at a rate of one event per 10.3 years. The three 278 
individual events that were considered cardiac-related events; the onset of CHF, aortic 279 
thromboembolism and sudden or unexpected death, occurred with similar frequency. In the 280 
population as a whole, fewer than one third of the affected cats experienced an event in a period of 281 
follow up of, on average, three years.  282 
Many previous studies have demonstrated the value of left atrial to aortic ratio as an indicator of 283 
cats at greater risk of an adverse outcome 4, 8, 10-12. In the current study this result was confirmed 284 
with cats having a LA:Ao ≥ 1.5 approximately 4 times more likely to experience a cardiac-related 285 
event. The current study also demonstrated that NTproBNP concentrations, when considered in 286 
isolation, were of similar predictive value to LA:Ao. Cats with a concentration ≥ 700 pmol/L were also 287 
approximately four times more likely to experience a cardiac-related event. These markers appeared 288 
to be complementary in their ability to identify cats at higher risk. Cats with values of both indicators 289 
above the cut-off were the most likely to experience an event and did so more quickly. 290 
In contrast to previous studies 13, 14 cTnI did not prove to be a useful indicator of the risk of a cardiac-291 
related event in this population. One possible reason for this is that the cats recruited to this study 292 
were all at the preclinical stage of their disease. If the release of troponin from myocardium is a late 293 
event in the course of HCM then it may only be a good indicator of risk in populations including 294 
those in the later stages of their disease i.e. those not at the preclinical stage of the disease. Another 295 
possible reason for the lack of demonstrated association is that the population described in the 296 
current study is relatively small – however this cohort is larger and was followed for longer than 297 
both of those previously described 13, 14. 298 
Both of the identified risk indicators, LA:Ao and NTproBNP, were evaluated serially in this 299 
population. Cats that subsequently experienced a cardiac-related event appeared to have a greater 300 
absolute change and percentage change in LA:Ao in the time interval prior to their experiencing the 301 
event. This suggests there is value in serial monitoring of LA:Ao. However it is worth noting that 302 
fewer than two thirds of the cats (30 in total) contributed data to this analysis. Some cats had 303 
already experienced the event before they were re-examined or their owners chose not to return for 304 
subsequent examinations. Clearly serial measurements can only be of value in those patients in 305 
which they can be obtained. Methods of prognostication for cats that are only seen on a single 306 
occasion must also be used because cats may experience an event before they are re-examined and 307 
owners may not be willing to wait for a second examination before an opinion on their cat’s 308 
likelihood of experiencing an event is given. 309 
Unexpectedly those cats that experienced an event had a lower absolute change in NTproBNP 310 
concentration between their first and second revisit. This may be a consequence of there being an 311 
upper limit for the highest concentration of NTproBNP that can be registered by the assay involved. 312 
Cats with concentrations above 1500 pmol/L which had an increase in concentration would not be 313 
correctly identified by this method of measurement. This would mean the analysis would only 314 
correctly recognise elevations in cats that initially had lower concentrations, but not in those that 315 
initially had high concentrations. It makes it doubtful, using the current assay, that there will be 316 
value in serial measurement of NTproBNP in cats despite the concentrations measured at the first 317 
visit being good indicators of risk. 318 
It is interesting to note that the cut-off value in this study proposed to distinguish cats at greater risk 319 
was 700 pmol/L. This is considerably higher than cut-offs that were previously proposed to 320 
distinguish cats in heart failure from those with respiratory distress due to other causes, and higher 321 
than cut-offs proposed to distinguish cats with preclinical cardiomyopathy from cats without 322 
cardiomyopathy20. There may be several reasons for this, firstly the feline NTproBNP assay has been 323 
through several iterations and it may be that absolute values obtained from earlier versions of the 324 
assay are not directly comparable to those from more recent iterations. Secondly every cat in the 325 
current study was known to have heart disease and the differentiation being made is between those 326 
with “worse” heart disease and milder heart disease. This may mean that a higher cut-off is required 327 
to distinguish those two groups compared to a cut-off being used to distinguish cats without heart 328 
disease from those with heart disease. 329 
Treatment with atenolol was offered to cats in which an elevated left ventricular outflow tract 330 
velocity was found because at the time our study was designed it was believed that beta-blockade 331 
may improve outcome in cats with preclinical hypertrophic obstructive cardiomyopathy and such 332 
treatment was widely recommended by cardiologists21. Systematically withholding such treatment 333 
to cats in the study was considered unethical. However, as our study progressed a trial was 334 
published which failed to show a benefit of atenolol administration in cats with hypertrophic 335 
obstructive cardiomyopathy11. Treatment was not consistently administered in all cases in which it 336 
was prescribed. One clinical trial had suggested that once in heart failure, cats receiving atenolol did 337 
less well than those not receiving atenolol22 and for that reason treatment was withdrawn in cats 338 
where evidence of disease progression was found.  339 
A significantly greater proportion of cats that experienced an event received atenolol at some point 340 
in the duration of the study, but it should not be concluded that this represents a detrimental effect 341 
of the treatment. Treatment was not randomly allocated nor were investigators blinded to 342 
treatment allocation. It is possible that there was some degree of allocation bias, with cats 343 
administered treatment being somehow different to those to which treatment was not 344 
administered.  345 
The current study has several limitations. 346 
The number of cats followed in the study is relatively small, however there are very few large 347 
prospective studies of cats with HCM in the literature and none conducted in a non-specialist 348 
setting. The low number of cats and the low event rate mean that the total number of cats 349 
experiencing events contributing to the analyses is only 15. The low number of events means that 350 
sub-analyses of the three separate cardiac-related events would not be worthwhile. It also means 351 
that multivariable analysis cannot be undertaken. The complementary value of measurement 352 
NTproBNP and LA:Ao is however suggested by analyses including the Kaplan Meier analysis and 353 
examination of the proportions of cats with none, one and two elevated risk indicators going on to 354 
experience an event. To conclusively demonstrate an independent and complementary value of the 355 
two tests a larger study with a greater number of events would be required. 356 
The diagnosis of HCM was made using published guidelines by cardiologists with an advanced post-357 
graduate qualification in cardiology, but was not confirmed by a specialist or by post-mortem 358 
examination. Two investigators made the diagnoses and carried out the follow up examinations on 359 
the cases described, however the agreement between the two investigators and the reproducibility 360 
of their findings was not evaluated. 361 
The study was conducted over a long period of time, during which the assay for the measurement of 362 
Feline NTproBNP was changed. This may have introduced a confounding factor particularly in the 363 
evaluation of serial concentrations. The duration of the period over which the study was conducted 364 
also resulted in the recommendations for treatment of preclinical HCM and prevention of ATE 365 
changing during the period of the study. Treatment was therefore variable over the period of the 366 
study and conclusions regarding the efficacy of treatment cannot be made. 367 
The diagnosis of ATE was made on the basis of clinical signs in the majority of cases and post-368 
mortem examination or advanced imaging were not performed. A diagnosis of sudden death was 369 
made on the basis of the owner’s description and presumed to be cardiac in origin. The diagnosis of 370 
CHF was made on the basis of clinical presentation and response to therapy and was not confirmed 371 
by diagnostic imaging in every case. Confirmation of a diagnosis of CHF can be challenging in cats 372 
and the performance of diagnostic imaging is not possible in every case, especially at the time of an 373 
emergency presentation for breathlessness. 374 
Conclusions 375 
In conclusion this study has demonstrated that a larger left atrium and/or higher concentrations of 376 
NTproBNP on initial examination of cats with preclinical HCM indicates cats at higher risk of 377 
experiencing CHF, ATE or sudden cardiac death. In cats that underwent serial measurement of LA:Ao 378 
those with increasing left atrial size had a greater risk of experiencing the same events compared to 379 
those in which left atrial size was static or reduced. Although the measurement of LA:Ao requires 380 
ultrasound equipment and expertise, the measurement of NTproBNP is widely available (through a 381 
diagnostic laboratory) and may help to identify patients with preclinical HCM at greater risk when 382 
echocardiography is not available. 383 
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